miR-155 in turn released by mononuclear cells can be taken up by neuroblastoma cells, reducing expression of the telomerase inhibitor telomeric repeat-binding factor 1 (TERF1), enhancing the activity of telomerase and promoting drug resistance in tumor cells (Challagundla et al., 2015). The gene discussed is TERF1; the disease is neoplasm.